Summary of IAC FY Conference Call - August 13, 2025 Company Overview - **Company**: IAC (InterActiveCorp) - **Key Businesses**: - People Inc (formerly Dotdash Meredith) - Care.com - Vivien Health (healthcare staffing) - The Daily Beast - Search business - **Financial Position**: $900 million in cash at the parent level with no debt at the parent level, although there is debt at People Inc which was refinanced attractively in June [10][11][12] Rebranding and Digital Transition - **Rebranding**: Transition from Dotdash Meredith to People Inc aimed at simplifying the brand for better recognition and marketability [5][6][13][15] - **Digital Focus**: The company is transitioning from print to digital, with a significant reduction in print publications from 12-13 to 7 over three years. The print business is maintained for branding and cash flow purposes [18][19][20] - **Digital Revenue**: 64% of the company's digital revenue comes from owned and operated (O&O) websites, with a focus on diversifying traffic sources beyond Google [25][28] Growth and Future Opportunities - **Long-term Goals**: Targeting 10% digital growth, with potential upside through new brands and leveraging consumer data [31][33] - **Decipher Tool**: An ad targeting tool that utilizes first-party data to enhance advertising effectiveness, potentially increasing the total addressable market (TAM) for ad sales [33][82] - **Care.com Growth**: Aiming for 10-20% growth in the consumer segment by improving product offerings and marketing strategies [94][97] Advertising Market Insights - **Market Conditions**: The advertising market is described as "good, not great," with sector-specific performance. Health and pharma are solid, while CPG and food and beverage sectors are facing challenges [68][71] - **Programmatic Advertising**: Programmatic revenue accounts for about 25-30% of total digital revenue, with recent improvements noted in pricing and demand [75][77] Strategic Partnerships and Licensing - **LLM Licensing**: The company is exploring licensing deals with LLM (Large Language Model) providers, emphasizing the need for high-quality content and potential economic arrangements [39][41] - **Cloudflare Partnership**: A partnership aimed at blocking LLM crawlers, except for OpenAI, has led to increased discussions with other LLM providers about accessing content [40] Financial Management and Shareholder Value - **Share Repurchases**: The company has been cautious with share buybacks, having repurchased $200 million worth of stock earlier in the year, while also considering M&A opportunities [58][59] - **Corporate Overhead**: Targeting a reduction in corporate overhead expenses, aiming for a run rate of $80-90 million by year-end [63][65] Key Business Segments - **Vivien Health**: Positioned as a strategic asset in healthcare staffing with a marketplace model connecting nurses and healthcare systems, currently generating mid-eight figures in revenue [99][100] - **Care.com**: Focused on stabilizing and growing the consumer segment after a decline in subscribers, with a new CEO implementing product improvements [96][97] Conclusion - The company is optimistic about its future growth prospects, leveraging its strong brand portfolio and digital capabilities to navigate the evolving media landscape [36][56]

Financial Data and Key Metrics Changes - The company reported total revenue of $130 million for Q2 2025, reflecting a 14% year-over-year growth [8][31] - Testing revenue also grew by 14% year-over-year, amounting to $122.3 million, driven by significant growth in Decipher and Afirma [31] - Adjusted EBITDA margin reached 27.5%, significantly exceeding expectations [9][35] - Non-GAAP gross margin was 71.5%, up approximately 30 basis points compared to the prior year [33] Business Line Data and Key Metrics Changes - Decipher tests delivered approximately 25,500 tests, achieving a year-over-year volume growth of 28% [10][11] - Afirma volume growth increased by 8% year-over-year, resulting in approximately 16,950 tests [17] - Prosigna is set to launch as an LDT in the U.S. breast cancer market in mid-2026, targeting a large patient population [21][22] Market Data and Key Metrics Changes - The company believes it holds a 65% market share in the prostate testing market, with Decipher positioned as the leading brand among clinicians [16] - The NCCN high-risk patient population is estimated to be approximately 25% of the incidence population, indicating a significant growth opportunity [13] Company Strategy and Development Direction - The company aims to transform cancer care globally through strategic initiatives focused on short-term, mid-term, and long-term growth drivers [9][29] - Plans include expanding the MRD testing platform and launching innovative products like the Percepta nasal swab for lung cancer [23][28] - The company is committed to geographic expansion and enhancing its research and development capabilities [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Decipher's long-term growth trajectory, anticipating sustained double-digit growth driven by market penetration and share gains [16][55] - The company expects to generate approximately $13 million in savings compared to 2024 results, which will be reinvested in growth drivers [37] - The updated 2025 total revenue guidance is set at $496 million to $500 million, reflecting strong performance in the first half of the year [38] Other Important Information - The company has scanned over 90,000 slides from over 50,000 de-identified patients to support ongoing research in digital pathology [15][104] - The sale of the Veracyte SaaS manufacturing business was completed on August 1, allowing for continuity of supply for the Prosigna IVD [26][36] Q&A Session Summary Question: What are the key drivers for maintaining Decipher's growth? - Management highlighted market penetration, share gains, and digital pathology integration as key drivers for sustaining growth [45][49] Question: What is the expected growth contribution from the metastatic population for Decipher? - Management indicated that while the metastatic launch is promising, it is not expected to have a significant impact in 2025, with more substantial contributions anticipated in 2026 and beyond [58][65] Question: What milestones will drive greater adoption and revenue growth for Prosigna? - Key milestones include the mid-2026 launch, pivotal study results, and ongoing clinical studies to support the test [67][68] Question: How is the company approaching MRD testing? - The company plans to leverage its existing Decipher sales channel and cross-train sales representatives to target both academic and community oncology [79][80] Question: What feedback has been received regarding the digital pathology offering? - Initial feedback has been positive, with a focus on ensuring that digital pathology complements existing molecular diagnostics [100][102]

© 2025 Veracyte, Inc. All rights reserved. 1 ‐ ‐ ‐ © 2025 Veracyte, Inc. All rights reserved. 2 © 2025 Veracyte, Inc. All rights reserved. 3 © 2025 Veracyte, Inc. All rights reserved. 4 © 2025 Veracyte, Inc. All rights reserved. © 2025 Veracyte, Inc. All rights reserved. 5 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 © 2025 Veracyte, Inc. All rights reserved. 7 © 2025 Veracyte, Inc. All rights reserved. 6 • • • • • • • 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 © 2025 Veracyte, Inc. All rights reserved. 8 © 2025 Ve ...

Veracyte (VCYT) 2025 Conference Summary Company Overview - **Company**: Veracyte, a leader in molecular diagnostics focused on cancer care [3][4] - **Core Products**: Afirma (thyroid diagnostics) and Decipher (prostate cancer prognosis) [5][6] Industry Insights - **Market Dynamics**: The cancer diagnostics market is expanding, with Veracyte aiming to serve patients globally, not just in the U.S. [3][4] - **Patient Impact**: Over 600,000 patients served to date, with significant clinical evidence supporting the utility of their tests [5][6] Financial Performance - **2024 Performance**: Achieved 28% testing revenue growth and a 20.6% adjusted EBITDA margin [5][19] - **Q1 2025 Performance**: Continued momentum with 19% testing revenue growth, marking the eleventh consecutive quarter of over 20% testing volume growth [6][18] - **Revenue Composition**: Decipher and Afirma accounted for 95% of total revenue in 2024 [6] Product Development and Pipeline - **Decipher Growth**: Over 275,000 patients tested, with a 45% CAGR from 2019 to 2024; aims for 80% market penetration [7][8] - **Afirma Updates**: Over 350,000 patients tested, with 60% avoiding unnecessary surgeries; expects high single-digit revenue growth [10][11] - **New Products**: Prosigna for breast cancer and MRD tests for muscle invasive bladder cancer are in development [13][15] Market Expansion - **Geographic Strategy**: Plans to launch tests in Europe, targeting HR positive breast cancer and prostate cancer markets [16][17] - **Innovative Solutions**: Development of the Percepta nasal swab for lung cancer detection, addressing a significant market need [17] Competitive Landscape - **MRD Competition**: Acknowledges competition but emphasizes differentiation through a whole genome approach and existing channels [31][34] - **Market Potential**: The MRD market is large, and Veracyte aims to carve out a significant share despite being a late entrant [32][34] Future Outlook - **2025 Guidance**: Anticipates 12% to 15% testing revenue growth for the full year, with adjusted EBITDA guidance raised to 22.5% [19][20] - **Long-term Goals**: Focused on achieving a 25% adjusted EBITDA margin and expanding product offerings [20][34] Key Takeaways - **Investor Perception**: The growth potential of pipeline products like MRD and Prosigna may not be fully recognized by investors [22][24] - **Capital Allocation**: Actively assessing M&A opportunities, with a high bar for potential targets [26][28] - **Resource Management**: Internal prioritization of resources is a challenge due to numerous growth opportunities [29]

Summary of Veracyte Conference Call Company Overview - **Company**: Veracyte - **Industry**: Molecular diagnostics, specifically focused on cancer care Core Points and Arguments 1. **Mission and Vision**: Veracyte aims to transform cancer care through specialized molecular diagnostics, focusing on generating actionable insights for clinicians to improve patient treatment outcomes [6][7] 2. **Testing Portfolio**: The company offers a range of diagnostic tests for various cancers, including thyroid, prostate, bladder, and breast cancer, with a focus on early detection and treatment monitoring [8] 3. **Patient Impact**: Veracyte has served 600,000 patients and has over 500 publications validating the performance of its tests, which supports commercial adoption and a strong financial profile [9] 4. **Financial Performance**: In 2024, Veracyte achieved 28% testing revenue growth and a 20.6% adjusted EBITDA margin, with core products Afirma and Decipher accounting for 95% of total revenue [9] 5. **Decipher Test Growth**: The Decipher test for prostate cancer saw a 37% volume growth in Q1, with over 275,000 patients tested. The market for prostate cancer is estimated to be 40% penetrated, with Decipher holding about 65% market share [10][11] 6. **Afirma Test Performance**: Afirma, the market leader in thyroid diagnostics, has tested over 350,000 patients, with 60% avoiding unnecessary surgeries. The market is estimated to be 65% penetrated, with Afirma holding 52% market share [13][14] 7. **Product Development Pipeline**: Veracyte has a robust pipeline, including the launch of Prosigna for breast cancer and MRD tests for bladder cancer, with commercial launches expected in 2026 [16][18] 8. **Geographic Expansion**: The company plans to expand its tests as IVDs in Europe, targeting significant patient populations for both breast and prostate cancer [19][20] 9. **Innovative Products**: The Percepta nasal swab for lung cancer is in development, addressing a large market of incidental lung nodules and aiming to improve early risk classification [20][21] Financial Outlook 1. **Revenue Growth**: Veracyte expects 12% to 15% testing revenue growth in 2025, with adjusted EBITDA margin guidance raised to 22.5% [22] 2. **Profitability Strategy**: The company is focused on balancing growth with financial discipline, aiming for a long-term adjusted EBITDA target of 25% [23][29] 3. **Cost Management**: Initiatives include a COGS reduction roadmap and transitioning to more cost-effective sequencing technology for Afirma [15][28] Additional Insights 1. **Market Dynamics**: The Decipher test is evolving from a prognostic tool to a clinical decision support tool, enhancing its role in managing prostate cancer [34][35] 2. **Reimbursement Landscape**: Continuous efforts are being made to improve reimbursement coverage, which is crucial for sustaining revenue growth [39][40] 3. **Organizational Readiness**: The company is preparing its sales teams for new product launches while maintaining profitability [31][33] This summary encapsulates the key points discussed during the Veracyte conference call, highlighting the company's strategic direction, financial performance, and growth initiatives in the molecular diagnostics industry.

Financial Data and Key Metrics Changes - The company reported adjusted EBITDA guidance of $330 million to $350 million for the full year, with a trailing basis of $309 million [40][41] - Free cash flow conversion remains strong, with a minor amount of capital expenditures and working capital [41] - The company has a net credit facility of $1.2 billion to $1.4 billion and aims to deleverage below four times leverage by year-end [41] Business Line Data and Key Metrics Changes - Dotdash Meredith is the number one digital and print publisher in America, with over $1.8 billion in majority digital revenue [23] - The company has seen consistent digital revenue growth, reporting a 7% increase in the first quarter and guiding for 7% to 9% growth for Q2 [39][40] - Care.com has flat revenue over the last few years, but the company expects improvements with a new management team and better marketing strategies [47] Market Data and Key Metrics Changes - The company noted strength in premium direct advertising revenue, particularly in health and beauty sectors, while experiencing weakness in food and beverage and parts of retail [60] - Programmatic advertising prices have stabilized after initially rising, indicating a shift in market dynamics [60] - MGM Resorts is viewed as undervalued, trading at about 3.3 times the current value of its properties, with significant upside potential [44] Company Strategy and Development Direction - The company is focused on capital allocation, including stock buybacks and strategic acquisitions, while also considering opportunistic divestitures [18][54] - Management changes have been made to enhance execution and focus on free cash flow [15][16] - The company aims to unlock the perceived value of its private assets and reduce the discount at which its equity trades [13][14] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a strong performance in direct premium advertising and a solid position heading into the latter part of the year [62] - The company anticipates some softness in Q2 and Q3 but expects relative strength in Q4, with no significant recession predicted [56] - Management highlighted the importance of resolving tariff issues to improve market conditions [62] Other Important Information - The company has a strong cash position with $900 million available at the holding company level [13] - The integration challenges faced by Dotdash Meredith have been addressed, leading to improved performance [10] - The company is actively exploring M&A opportunities across various stages and sectors, particularly in leisure, entertainment, and media [21] Q&A Session Summary Question: Can you walk through the macro environment regarding tariffs? - Management noted that there was strength in March, but volatility has since increased, with premium direct advertising remaining solid despite some weakness in other sectors [59][60] Question: Is there a path for IAC to take a controlling stake in Turo? - Management indicated that taking a controlling stake is not a priority, focusing instead on executing current opportunities [63] Question: Are there discussions with other large language model developers? - Management confirmed ongoing discussions with various developers, with OpenAI being the most advanced partner [64][65]

Core Insights - Veracyte's shares have increased by 30.9% over the past year, outperforming the industry's decline of 13.1% and the S&P 500's gain of 12.1% [1] - The company holds a Zacks Rank 3 (Hold) and continues to benefit from the strong performance of its Afirma and Decipher tests, indicating promising future growth potential [1] Company Overview - Veracyte, based in San Francisco, CA, specializes in advanced genomic tests that enhance diagnostic, prognostic, and treatment decisions for cancer and other complex diseases, ultimately helping patients avoid unnecessary procedures [2] - The company provides tests through its central laboratories in the U.S. while expanding global access via partnerships with local labs [2] Growth Catalysts - The increase in share price is attributed to the strong performance of Afirma and Decipher Prostate tests, with Afirma test volumes growing by 10% in Q1 2025, totaling approximately 15,500 tests [3] - The growth was primarily driven by deeper penetration into existing accounts and the addition of significant new customers [3] - Decipher has experienced a remarkable adoption rate, with a record volume growth of 37% year over year, resulting in nearly 22,600 tests and a 33% revenue growth in Q1 2025 [4] - Veracyte is expanding its tests to cover the entire prostate cancer risk spectrum, with plans to launch into this expanded population in the first half of 2025 [5] Financial Estimates - The Zacks Consensus Estimate for Veracyte's 2025 earnings per share (EPS) has increased by 18.5% to $1.28, with projected revenues growing by 10.7% to $493.3 million in 2025 and reaching $542.8 million in 2026 [8]

Core Insights - Veracyte, Inc. reported a significant increase in first-quarter 2025 earnings, with earnings per share (EPS) of 31 cents, a 63.2% improvement from 19 cents in the same period last year, and exceeding the Zacks Consensus Estimate by 55% [1] - The company achieved revenues of $114.5 million, reflecting an 18.3% year-over-year increase, surpassing the Zacks Consensus Estimate by 3.2% [2] - The company reaffirmed its full-year 2025 testing revenue guidance, expecting revenues between $470 million and $480 million, indicating a 12-15% year-over-year growth [7] Financial Performance - Adjusted EPS was reported at 9 cents, compared to a loss of 2 cents per share in the prior year [1] - Testing revenues reached $107.3 million, a 19% increase year-over-year, driven by Decipher and Afirma revenue growth of 33% and 6%, respectively [2] - Gross profit rose by 27.3% to $79.5 million, with gross margin expanding by 495 basis points to 69.5% [4] Cost and Expenses - Total cost of revenues was $35 million, up 1.7% year-over-year [4] - Selling and marketing expenses increased by 2.8% to $24.4 million, while general and administrative expenses rose by 29% to $33.8 million [5] - Research and development expenses totaled $17.7 million, an 11% increase year-over-year [5] Cash and Solvency - At the end of Q1 2025, Veracyte had cash and cash equivalents of $186.1 million, down from $239.1 million at the end of Q4 2024 [6] - The net cash provided from operating activities was $5.4 million, compared to a net cash used of $9 million in the previous year [6] Strategic Developments - The company launched Decipher for metastatic prostate cancer patients and published analytical validity data for the Percepta Nasal Swab during the first quarter [10] - The growth in product revenues and biopharmaceutical revenues, which also increased by 19% to $3.6 million, is seen as encouraging [3]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $114.5 million, representing an 18% year-over-year growth, driven by testing revenue growth of 19% year-over-year [6][28] - Adjusted EBITDA margin was 21.6%, significantly higher than expected, with a strong balance sheet of $287 million in cash and short-term investments [6][28] - Non-GAAP gross margin was 72%, up approximately 400 basis points year-over-year, while testing gross margin was 74%, up approximately 200 basis points [31] Business Line Data and Key Metrics Changes - Decipher saw a 37% year-over-year volume growth, resulting in approximately 22,600 tests and revenue growth of 33% [7][9] - Afirma experienced a 10% year-over-year volume growth, resulting in approximately 15,500 tests, but revenue growth was lower at 6% due to prior period collection benefits [12][66] - Product line revenue was $3.6 million, up 1% year-over-year, while biopharmaceutical and other revenue was also $3.6 million, up 19% year-over-year [30] Market Data and Key Metrics Changes - The company reported a record number of ordering providers for Decipher, up over 20% from the prior year, indicating strong market penetration [7][60] - The Decipher prostate metastatic test is expected to expand the population eligible for testing by an additional 30,000 patients annually [10] - The MRD platform is being developed for muscle invasive bladder cancer, with a commercial launch expected in the first half of 2026 [17] Company Strategy and Development Direction - The company is focused on expanding its existing tests, Decipher and Afirma, and launching new products like Prosigna in the U.S. breast cancer market [15][16] - Strategic initiatives include international expansion and addressing novel cancer challenges with innovative products [6][25] - The company aims to leverage its Veracyte Diagnostics platform to generate clinical evidence and support product adoption [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong growth despite a challenging macro environment, citing ongoing durability in core testing business [6][34] - The company reiterated its 2025 testing revenue guidance of $470 million to $480 million, raising adjusted EBITDA margin guidance to 22.5% [33][34] - Management highlighted the importance of evidence generation and reimbursement in ensuring successful product launches [49][90] Other Important Information - The company is undergoing a restructuring process in France, with its subsidiary Veracyte SAS filing for bankruptcy, which may impact product development timelines [21][22] - The launch of the Prosigna LDT is expected in mid-2026, targeting over 300,000 patients diagnosed with breast cancer annually in the U.S. [15][16] Q&A Session Summary Question: Thoughts on portfolio optimization and pipeline value of MRD and nasal swab - Management emphasized a focus on portfolio management and expanding indications, with confidence in the pipeline value of MRD and nasal swab initiatives [36][38][42] Question: Organizational readiness for upcoming product launches - Management discussed the importance of evidence generation and thoughtful launch plans, ensuring investments align with growth opportunities [48][49][53] Question: Clarification on guidance and Afirma growth rate - Management clarified that the guidance reflects testing revenue only, with expectations of high single-digit growth for Afirma [62][66] Question: Differentiation of Prosigna in a competitive market - Management highlighted the evidence-based differentiation of Prosigna and the strategy to gain market share similar to Decipher's success [72][75]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $114.5 million, representing an 18% year-over-year growth, driven by testing revenue growth of 19% year-over-year [5][28] - Adjusted EBITDA margin was 21.6%, significantly higher than expected, with a strong balance sheet of $287 million in cash and short-term investments [5][28] - Non-GAAP gross margin was 72%, up approximately 400 basis points year-over-year, while testing gross margin was 74%, up approximately 200 basis points [30][32] Business Line Data and Key Metrics Changes - Decipher testing revenue grew by 33% year-over-year, with volume growth of 37%, totaling approximately 22,600 tests [6][28] - Afirma testing volume increased by 10% year-over-year, resulting in approximately 15,500 tests, but revenue growth was lower due to prior period collection benefits [12][28] - Product line revenue was $3.6 million, up 1% year-over-year, while biopharmaceutical and other revenue was also $3.6 million, up 19% year-over-year [29] Market Data and Key Metrics Changes - The company reported a record number of ordering providers for Decipher, up over 20% from the prior year, indicating strong market penetration [6][28] - The Decipher prostate metastatic test is expected to launch broadly in June 2025, expanding the population eligible for testing [9][10] - The MRD platform is advancing with a focus on muscle invasive bladder cancer, with commercial launch expected in the first half of 2026 [18][19] Company Strategy and Development Direction - The company is focused on expanding its existing tests, Decipher and Afirma, and launching new products like Prosigna in the U.S. breast cancer market [16][17] - Strategic initiatives include international expansion and addressing novel cancer challenges with innovative products [6][25] - The company aims to leverage its Veracyte Diagnostics platform to generate clinical evidence and support product adoption [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong growth despite a challenging macro environment, citing positive trends in testing volume and provider engagement [5][6] - The company reiterated its 2025 testing revenue guidance of $470 million to $480 million, raising adjusted EBITDA margin guidance to 22.5% [33][34] - Management emphasized the importance of evidence generation and reimbursement for new product launches, ensuring organizational readiness for upcoming launches [48][52] Other Important Information - The company is undergoing a bankruptcy process for its French subsidiary, Veracyte SAS, which will not impact its overall strategy or revenue models for the next five years [21][24] - The launch of the Prosigna LDT is expected to begin in mid-2026, targeting a significant market of over 300,000 breast cancer patients annually in the U.S. [16][17] Q&A Session Summary Question: Thoughts on portfolio optimization and pipeline value of MRD and nasal swab - Management is focused on portfolio management, ensuring investments have appropriate evidence and reimbursement, and is excited about the broad pipeline of new products [37][40] - The MRD and nasal swab initiatives are seen as having significant market potential, with upcoming milestones expected to validate their value [42][43] Question: Organizational readiness for upcoming product launches - The company has a thoughtful launch plan in place, ensuring that investments are made in line with growth opportunities and that commercial activities are well-prepared [48][52] Question: Clarification on guidance and growth expectations for Afirma - Afirma is expected to see high single-digit revenue growth for the year, with volume growth driven by prior period collections and market dynamics [66][67] Question: Differentiation of Prosigna in a competitive market - Management believes Prosigna is differentiated based on evidence generation and a strong playbook similar to Decipher, aiming to gain market share in the U.S. [73][75]